CompletedNCT02918318
Esketamine Nasal Spray Added to Antidepressants for Japanese Adults With Treatment-Resistant Depression
About this title
Read the official source —Medication studyAges 20–64Japan
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 20 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Akita and 42 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: December 12, 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 202
- Sponsor
- Janssen Pharmaceutical K.K.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Japan
- Age range
- From 20 Years to 64 Years
- Official registry ID
- NCT02918318
- Official title
Show the full official title
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Subjects With Treatment Resistant Depression
Get this study by email
Recruitment & locations
CompletedAkita · Fukui-shi · Fukuoka
40 more locations
- Gunma
- Hachinohe-shi
- Hachioji-shi
- Hirakata
- Hiratsuka-shi
- Hokkaido
- Ibaraki
- Ichikawa
- Kanzaki-gun
- Karatsu
- Kashihara
- Kawasaki
- Kita-Azumi
- Kita-ku
- Kitakyushu
- Kobe
- Kochi
- Kodaira
- Komoro-shi
- Kumamoto
- Kure
- Kurume-shi
- Kyoto
- Maizuru
- Morioka
- Nagakute
- Nagasaki
- Okayama
- Okinawa
- Osaka
- Sapporo
- Setagaya-ku
- Shibuya-ku
- Shinjuku
- Shinjuku-ku
- Takatsuki-shi
- Toyoake
- Ube
- Yokohama
- Yonago
Questions about this study
Who is behind this study?
The study sponsor is Janssen Pharmaceutical K.K., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Placebo, Intranasal esketamine (28 mg), Intranasal esketamine (56 mg) and Intranasal esketamine (84 mg).
Who was this study for?
This study was for people with depression. Listed age limits: 20 years to 64 years. Other eligibility criteria applied.
